Salem et al. (2017) reported a blood biomarker panel containing interleukin (IL)-1b, neutrophil count, and cytokeratin-19 antigen to predict lung cancer radiotherapy response. Saito et al. (2014) constructed a three-microRNA signature to predict responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Liu et al. (2019) identified a miRNA signature by an in vitro system to assess radiosensitivity for head and neck squamous cell carcinomas and validated this signature using the TCGA database (Ning et al., 2015). This evidence concerns the gene KRT19 and lung adenocarcinoma.